Roche remains the most sustainable healthcare company in the Dow Jones Sustainability Indices

By Catherine Sturman
For the tenth consecutive year, Roche has been recognised as the most sustainable company in the Pharmaceuticals index of the Dow Jones Sustainability I...

For the tenth consecutive year, Roche has been recognised as the most sustainable company in the Pharmaceuticals index of the Dow Jones Sustainability Indices (DJSI).

The largest biotech company in the world, 30 medicines developed by the company are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines.

Based on an in-depth analysis of economic, social and environmental performance, the company serves as a benchmark for investors who integrate sustainability considerations into their portfolios.

 “Our most important contribution to society is the development of medicines and diagnostics that significantly improve people's lives. Open and constructive dialogue with other companies, universities, doctors and patients plays an essential role here in understanding the needs of our partners in the healthcare sector and enabling us to work together to develop more targeted medical solutions faster,” said Roche CEO Severin Schwan.

See also

One example is Roche’s partnership with the Michael J. Fox Foundation for Parkinson's Research (MJFF). Since 2010, Roche has been actively supporting the Parkinson's Progression Marker Initiative (PPMI) as part of a collaboration between companies, non-profit organisations and private individuals.

Through this partnership, Roche will soon start to offer study participants access to its digital biomarker platform, which monitors symptoms of disease progression. The anonymised data collected by the technology will be published by the PPMI publicly on a regular basis, for the whole research community – including Roche’s competitors - to access.

The hope is that this will enable the business to better investigate disease progression, speed up clinical development and improve the treatment of Parkinson's disease by accelerating clinical studies and get urgently needed treatments to patients faster.

Roche follows a holistic approach when managing sustainability: In addition to improving access to products, the company’s strategy also focuses on achieving continuous progress in areas such as social responsibility, environmental protection, supply chain sustainability, people attraction and retention.

Share

Featured Articles

McKinsey: Women More Likely to die of Heart Attack Than Men

McKinsey Health Institute's Lucy Pérez says cardiovascular disease top killer of women yet physicians don't know their heart attack symptoms are different

Novo Nordisk Buys $1bn Cardior in CardioVascular Move

As Novo Nordisk expands into heart medicines, we profile the Danish pharma giant who in 1923 was the first to make insulin commercially available

Shoddy Chinese Syringes Sees BD Ramp-up Production

Becton Dickinson – a major supplier of syringes – said it has upped manufacturing in its US facilities after FDA warning on China-made products

AI Tool 'Picks up Early-stage Breast Cancers Doctors Missed'

Technology & AI

AstraZeneca Buys $2bn Fusion in Next-gen Cancer Drugs Move

Medical Devices & Pharma

Eli Lilly and Amazon Pharmacy Partner on Drugs Delivery

Digital Healthcare